Essential Thrombocythemia (ET) Global Market Report 2025
상품코드:1730853
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
본태성 혈소판 증가증(ET) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 6.1%로 성장할 전망이며, 11억 2,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장은 본태성 혈소판 증가증의 인지도 향상 및 조기 진단, 혈액학적 검사의 이용가능성 확대, 노인인구 증가, 헬스케어 지출 증가, 연방정부 지원금 증가 등에 기인하고 있습니다. 이 기간 주요 동향에는 기술의 진보, 유전자 프로파일링, 신규 표적 요법, 원격 의료의 진보, 전략적 제휴 등이 있습니다.
맞춤형 의료의 채용 확대가 본태성 혈소판 증가증(ET) 시장의 성장을 견인할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전적 체질, 라이프 스타일, 환경 요인에 근거해 치료나 예방 전략을 조정하는 것입니다. 이 접근법은 게놈, 바이오테크놀로지, 데이터 해석의 진보로 보다 정확한 진단과 표적 치료를 가능하게 하기 위해 일반적으로 되고 있습니다. 본태성 혈소판 증가증의 경우 맞춤형 의료를 통해 유전자 변이에 맞는 치료가 가능해 치료의 정확도가 높아지고 환자의 전귀가 개선됩니다. 예를 들어 2024년 2월 개별화의료연합(Personalized Medicine Coalition)은 FDA가 희귀질환에 대한 새로운 맞춤형 요법을 2022년에는 단 6건에서 2023년에는 16건 승인했다고 보고했습니다. 그 결과 개별화 의료의 채용이 증가하여 ET 시장의 성장에 기여하고 있습니다.
본태성 혈소판 증가증 시장에서 사업을 전개하는 기업은 치료 효과 및 환자 결과를 개선하고 이용 가능한 치료법의 범위를 확대하기 위해 bomedemstat의 3상 임상시험을 포함한 신규 치료제 개발에 점점 주력하고 있습니다. 이러한 후기 임상시험에서 LSD1 억제제인 bomedemstat의 안전성과 효능은 고급 치료 옵션이 필요한 환자를 대상으로 평가됩니다. 예를 들면, 2024년 8월에 Merck & Co. Inc.는 본태성 혈소판 증가증 치료를 목적으로 한 bomedemstat의 3상 임상시험인 Shorespan-007의 시작을 발표했습니다. 본 시험은 과거에 세포 감소 요법을 받지 않은 환자를 대상으로 하고 있습니다. 본 시험의 모집은 개시되어 환자의 등록은 현재 진행중입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 본태성 혈소판 증가증(ET) 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 본태성 혈소판 증가증(ET) 시장 : 성장률 분석
세계의 본태성 혈소판 증가증(ET) 시장 실적 : 규모 및 성장(2019-2024년)
세계의 본태성 혈소판 증가증(ET) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 본태성 혈소판 증가증(ET) 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 본태성 혈소판 증가증(ET) 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
인터페론
아나그렐리드
히드록시우레아
아스피린
세계의 본태성 혈소판 증가증(ET) 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
혈액 검사
골수 생검
유전자 변이 분석
기타
세계의 본태성 혈소판 증가증(ET) 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
연구기관
전문 클리닉
세계의 본태성 혈소판 증가증(ET) 시장 : 인터페론 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
페그 인터페론
표준 인터페론
병용 요법
세계의 본태성 혈소판 증가증(ET) 시장 : 아나그렐리드 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단제요법
아스피린과의 병용
용량 조절 요법
세계의 본태성 혈소판 증가증(ET) 시장 : 히드록시우레아 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
저용량 요법
고용량 요법
항혈소판제과의 병용
세계의 본태성 혈소판 증가증(ET) 시장 : 아스피린 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
저용량 아스피린
고용량 아스피린
세포 체중 감소 요법과의 병용
제7장 지역별 및 국가별 분석
세계의 본태성 혈소판 증가증(ET) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 본태성 혈소판 증가증(ET) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
본태성 혈소판 증가증(ET) 시장 : 경쟁 구도
본태성 혈소판 증가증(ET) 시장 : 기업 프로파일
Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Novartis AG
Sanofi SA
GlaxoSmithKline plc
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Astellas Pharma Inc.
Fresenius Kabi AG
Incyte Corporation
Vifor Pharma Management AG
Bio-Techne Corporation
Argenx SE
AOP Orphan Pharmaceuticals AG
Orchard Therapeutics plc
Medunik USA.
Kartos Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
본태성 혈소판 증가증(ET) 시장(2029년) : 새로운 기회를 제공하는 국가
본태성 혈소판 증가증(ET) 시장(2029년) : 새로운 기회를 제공하는 부문
본태성 혈소판 증가증(ET) 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of platelets in the bone marrow. This condition increases the risk of blood clots, bleeding complications, and potential progression to myelofibrosis or leukemia. Ongoing monitoring and treatment are required to manage symptoms and prevent complications.
The main treatment options for essential thrombocythemia (ET) include interferon, anagrelide, hydroxyurea, and aspirin. Interferon refers to a group of proteins produced by the immune system that help modulate immune responses and inhibit abnormal cell growth. Diagnostic methods for ET include blood tests, bone marrow biopsies, gene mutation analysis, and other procedures. These are used by various end users, including hospitals, research organizations, and specialty clinics.
The essential thrombocythemia (ET) market research report is one of a series of new reports from The Business Research Company that provides essential thrombocythemia (ET) market statistics, including the essential thrombocythemia (ET) industry global market size, regional shares, competitors with the essential thrombocythemia (ET) market share, detailed essential thrombocythemia (ET) market segments, market trends, and opportunities, and any further data you may need to thrive in the essential thrombocythemia (ET) industry. This essential thrombocythemia (ET) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The essential thrombocythemia (ET) market size has grown strongly in recent years. It will grow from $0.83 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to the rising number of essential thrombocythemia cases, an increase in sickle cell anemia cases, higher investment in research and development, growing awareness among healthcare professionals, and the increasing popularity of related drugs.
The essential thrombocythemia (ET) market size is expected to see strong growth in the next few years. It will grow to $1.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to rising awareness and early diagnosis of essential thrombocythemia, greater availability of hematology testing, a growing geriatric population, increased healthcare expenditure, and rising federal funding. Key trends during this period include technological advancements, genetic profiling, novel targeted therapies, advancements in telemedicine, and strategic collaborations.
The increasing adoption of personalized medicine is expected to drive the growth of the essential thrombocythemia (ET) market. Personalized medicine tailors treatment and prevention strategies based on an individual's genetic makeup, lifestyle, and environmental factors. This approach is becoming more popular due to advancements in genomics, biotechnology, and data analytics, which enable more precise diagnostics and targeted therapies. In the case of essential thrombocythemia, personalized medicine allows for therapies tailored to genetic mutations, enhancing treatment accuracy and improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, compared to just six in 2022. As a result, the rising adoption of personalized medicine is fueling the growth of the ET market.
Companies operating in the essential thrombocythemia market are increasingly focused on developing novel therapeutics, including Phase 3 clinical trials for bomedemstat, to improve treatment efficacy, patient outcomes, and expand the range of available therapies. These late-stage trials assess the safety and effectiveness of bomedemstat, an LSD1 inhibitor, for patients requiring advanced treatment options. For instance, in August 2024, Merck & Co. Inc., a U.S.-based pharmaceutical company, announced the launch of Shorespan-007, a Phase 3 clinical trial of bomedemstat for treating essential thrombocythemia. The trial targets patients who have not received previous cytoreductive therapy. Recruitment for the trial has begun, and patient enrollment is currently underway.
In January 2023, Merck & Co. Inc. acquired Imago BioSciences Inc. for $1.35 billion to strengthen its hematology portfolio. This acquisition allows Merck to enhance its offerings for essential thrombocythemia and other blood-related disorders by integrating Imago BioSciences' innovative therapies. Imago BioSciences specializes in developing treatments for essential thrombocythemia, bolstering Merck's position in the development of targeted therapies for hematologic diseases.
Major players in the essential thrombocythemia (et) market are Hoffmann-La Roche AG, AbbVie Inc., Johnson & Johnson, Bayer AG, Bristol Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Fresenius Kabi AG, Incyte Corporation, Vifor Pharma Management AG, Bio-Techne Corporation, Argenx SE, AOP Orphan Pharmaceuticals AG, Orchard Therapeutics plc, Medunik USA., and Kartos Therapeutics Inc.
North America was the largest region in the essential thrombocythemia (ET) market in 2024. The regions covered in essential thrombocythemia (ET) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the essential thrombocythemia (ET) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The essential thrombocythemia (ET) market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and management services, and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The essential thrombocythemia (ET) market also includes sales of diagnostic products, therapeutic medications, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Essential Thrombocythemia (ET) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on essential thrombocythemia (et) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for essential thrombocythemia (et) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The essential thrombocythemia (et) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Interferon; Anagrelide; Hydroxyurea; Aspirin
2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Gene Mutation Analysis; Other Diagnosis
3) By End User: Hospitals; Research Organizations; Specialty Clinics
Subsegments:
1) By Interferon: Pegylated Interferon; Standard Interferon; Combination Therapy
2) By Anagrelide: Monotherapy; Combination With Aspirin; Dose-Adjusted Therapy
3) By Hydroxyurea: Low-Dose Therapy; High-Dose Therapy; Combination With Antiplatelet Agents
4) By Aspirin: Low-Dose Aspirin; High-Dose Aspirin; Combination With Cytoreductive Therapy
Companies Mentioned: Hoffmann-La Roche AG; AbbVie Inc.; Johnson & Johnson; Bayer AG; Bristol Myers Squibb Company
3. Essential Thrombocythemia (ET) Market Trends And Strategies
4. Essential Thrombocythemia (ET) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Essential Thrombocythemia (ET) Growth Analysis And Strategic Analysis Framework
5.1. Global Essential Thrombocythemia (ET) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Essential Thrombocythemia (ET) Market Growth Rate Analysis
5.4. Global Essential Thrombocythemia (ET) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Essential Thrombocythemia (ET) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Essential Thrombocythemia (ET) Total Addressable Market (TAM)
6.1. Global Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interferon
Anagrelide
Hydroxyurea
Aspirin
6.2. Global Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Bone Marrow Biopsy
Gene Mutation Analysis
Other Diagnosis
6.3. Global Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Organizations
Specialty Clinics
6.4. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Interferon, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pegylated Interferon
Standard Interferon
Combination Therapy
6.5. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Anagrelide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination With Aspirin
Dose-Adjusted Therapy
6.6. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Hydroxyurea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low-Dose Therapy
High-Dose Therapy
Combination With Antiplatelet Agents
6.7. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low-Dose Aspirin
High-Dose Aspirin
Combination With Cytoreductive Therapy
7. Essential Thrombocythemia (ET) Market Regional And Country Analysis
7.1. Global Essential Thrombocythemia (ET) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Essential Thrombocythemia (ET) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Essential Thrombocythemia (ET) Market
9.1. China Essential Thrombocythemia (ET) Market Overview
9.2. China Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Essential Thrombocythemia (ET) Market
10.1. India Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Essential Thrombocythemia (ET) Market
11.1. Japan Essential Thrombocythemia (ET) Market Overview
11.2. Japan Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Essential Thrombocythemia (ET) Market
12.1. Australia Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Essential Thrombocythemia (ET) Market
13.1. Indonesia Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Essential Thrombocythemia (ET) Market
14.1. South Korea Essential Thrombocythemia (ET) Market Overview
14.2. South Korea Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Essential Thrombocythemia (ET) Market
15.1. Western Europe Essential Thrombocythemia (ET) Market Overview
15.2. Western Europe Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Essential Thrombocythemia (ET) Market
16.1. UK Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Essential Thrombocythemia (ET) Market
17.1. Germany Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Essential Thrombocythemia (ET) Market
18.1. France Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Essential Thrombocythemia (ET) Market
19.1. Italy Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Essential Thrombocythemia (ET) Market
20.1. Spain Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Essential Thrombocythemia (ET) Market
21.1. Eastern Europe Essential Thrombocythemia (ET) Market Overview
21.2. Eastern Europe Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Essential Thrombocythemia (ET) Market
22.1. Russia Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Essential Thrombocythemia (ET) Market
23.1. North America Essential Thrombocythemia (ET) Market Overview
23.2. North America Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Essential Thrombocythemia (ET) Market
24.1. USA Essential Thrombocythemia (ET) Market Overview
24.2. USA Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Essential Thrombocythemia (ET) Market
26.1. South America Essential Thrombocythemia (ET) Market Overview
26.2. South America Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Essential Thrombocythemia (ET) Market
27.1. Brazil Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Essential Thrombocythemia (ET) Market
28.1. Middle East Essential Thrombocythemia (ET) Market Overview
28.2. Middle East Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Essential Thrombocythemia (ET) Market
29.1. Africa Essential Thrombocythemia (ET) Market Overview
29.2. Africa Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Essential Thrombocythemia (ET) Market Competitive Landscape And Company Profiles
